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INTRODUCTION
Ehrlichiosis is caused primarily by Ehrlichia chaffeensis and 
Ehrlichia ewingii.1,2 These obligate intracellular gram-negative cocco-
bacilli are transmitted by arthropod vectors. They reside in vertebrate 
reservoirs and undergo a tick-mammal-tick cycle during which 
humans are dead-end hosts. The life cycle of E. chaffeensis is perpetu-
ated predominantly via the A. americanum (Lone star) tick.1,2 During 
human infection, E. chaffeensis preferentially targets monocytes. Men 
are affected more often than women. Individuals between the ages 
of 65 and 69 had the highest incidence rate (IR) between 2008 and 
2012.1,3 During this period, Oklahoma and Missouri had the highest IR 
at 30.9 and 26.3 per million, respectively.3 Patients with hematologic 
malignancies undergoing chemotherapy can have similar symptoms 
to those found in ehrlichiosis without being infected. However, in 
the appropriate setting, tick-borne illness should be considered. We 
present a case of severe illness and prolonged fevers due to ehrlichio-
sis in a patient who received chemotherapy for chronic lymphocytic 
leukemia (CLL).
CASE REPORT
 A 77-year-old man with CLL who completed six cycles of benda-
mustine and rituximab three months prior, presented in early August 
with complaints of fevers, night sweats, decreased appetite, and nausea 
for one month and was found to have a white blood count (WBC) of 
1.5K/µL. This patient had asymptomatic persistent leukopenia fol-
lowing therapy into mid-May and mid-July. The patient was seen in 
the emergency department and in clinic by his oncologist, where he 
was febrile up to 39.3⁰C, and subjectively had fatigue, myalgias, and 
arthralgias. The work-up, including chest x-ray, blood cultures, and 
urinalysis, was negative. He was treated empirically with levofloxacin 
and amoxicillin-clavulanic acid. In addition, he received seven doses 
of filgrastim (human-granulocyte colony stimulating factor) during 
his course of antibiotics.
 After completion of antibiotics, the patient had a brief period of 
a few days where he felt well enough to proceed with vacation plans. 
During his vacation, his symptoms recurred and worsened quickly. He 
presented to clinic immediately after his vacation and noted darken-
ing of his urine secondary to presumed dehydration, in addition to his 
previous symptoms. At that time, his labs were significant for hypona-
tremia, elevated glucose, lactate dehydrogenase of 275 µ/L, AST of 56 
µ/L, ALT of 56 µ/L, alkaline phosphatase of 91 µ/L, a normal WBC, 
and a platelet count of 271 x 106 /µL. Attempts were made to manage 
at home, but with ongoing worsening of his condition after three days, 
he was instructed by his oncologist to be admitted to the hospital. 
 New symptoms on admission included altered mental status and 
insomnia. On admission, he was febrile and physical exam was per-
tinent for rales in bilateral lung bases, and he was without rash, focal 
neurological deficits, or lymphadenopathy. CT of his sinuses, chest, 
abdomen, and pelvis demonstrated no abnormal lymphadenopathy or 
nidus of infection. His labs were notable for normal white blood count 
of 5.2 K/µL, with a platelet count of 49,000 K/µL. Ferritin was > 7500 
ng/mL and his AST and ALT were 141 µ/L and 81 µ/L, respectively. 
 Based on his ferritin level, there was concern for hemophago-
cytic lymphohistiocytosis. A bone marrow biopsy demonstrated 
residual CLL without evidence of hemophagocytosis or macrophage 
predominance. On the second day of admission, infectious disease 
was consulted. They empirically started amphotericin, imipenem, and 
doxycycline. Over the next 24 hours, the patient worsened with persis-
tent fever, rigors, altered mental status, tachypnea, and a new oxygen 
requirement. Repeat chest imaging revealed pulmonary edema. 
 The patient was transferred to the intensive care unit for acute 
hypoxic respiratory failure. Infectious disease labs that were obtained 
on consultation at admission were positive for Ehrlichia chaffeensis by 
polymerase chain reaction. His antibiotics were narrowed to doxycy-
cline, the patient clinically improved over the course of two weeks, and 
his labs normalized after a 10-day course of doxycycline.
DISCUSSION
 Human ehrlichiosis is a clinical syndrome characterized by fever 
and cytopenias. The median incubation period is eight days. Only 57% 
of confirmed cases are associated with a known tick bite.4 Fever is 
a prominent symptom (96%) along with malaise (77%), headache 
(72%), and myalgias (68%). Rash is seen uncommonly at presentation 
(6%), but approximately 26% of patients will develop a rash. Other 
symptoms include gastrointestinal symptoms (25 - 57%), cough 
(28%), and confusion (20%). The mortality rate is approximately 
2%. Laboratory values can demonstrate an elevation in ALT and AST 
(84% of patients), leukopenia (61%), and thrombocytopenia (73%). 
Laboratory findings can include a mild-moderate elevation in alka-
line phosphatase and LDH.1,2,5 Diagnosis is commonly achieved using 
PCR which is most sensitive during early infection. Paired indirect 
fluorescence antibody (IFA) assays are considered the gold-standard 
for serologic diagnosis, but take weeks to perform.6
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Our patient’s course was longer than most and he had a period of 
brief improvement. He experienced approximately 20 days of relaps-
ing fevers and worsening symptoms prior to hospitalization. A case 
series of ehrlichiosis as a cause of a prolonged fever found fevers 
ranged between 17 - 51 days.7 The patients in this series had various 
clinical manifestations, but defervescence occurred shortly after dox-
ycycline therapy. One of these patients had the illness resolve after 30 
days of a relapsing fever. 
 Case reports on whether ehrlichiosis is more severe in immuno-
compromised individuals are conflicting.8,9 A retrospective study by 
Thomas et al.8 found no significant difference in ICU admissions, 
duration of hospital stay, presenting lab values, or severity of illness 
between immune competent and immunosuppressed patients. 
Conversely, Safdar et al.9 found a 25% mortality rate for immune com-
promised individuals. In addition, they found that almost all 23 cases 
reviewed demonstrated significant organ dysfunction. Finally, a 2016 
analysis of national surveillance data for Ehrlichia chaffeensis infec-
tions showed an increased risk of hospitalization, life-threatening 
complications, and death among immune compromised individu-
als.3 This patient developed pulmonary edema and pleural effusions. 
Several case series found that pleural effusions or pulmonary involve-
ment may be more common in the immunocompromised population 
manifesting as abnormal pulse oximetry, or abnormal pulmonary 
examination.4,5,10-12 A delay in diagnosis and by extension a delay in 
the administration of doxycycline, may explain the difference in sever-
ity. Delayed doxycycline therapy is associated with increased rates of 
ICU transfers, rates of mechanical ventilation, longer hospital stays, 
and overall length of illness.13
 Lastly, filgrastim is associated with relatively common adverse 
effects of bone pain, fatigue, headache, and fever.14 His frequent injec-
tions with filgrastim early in the clinical course may have complicated 
the initial presentation by boosting his WBC count and, to some 
extent, his platelets and the non-specific adverse effects.
CONCLUSION
 Our patient’s diagnosis was nebulous secondary to a recent history 
of cytotoxic chemotherapy and immune modulating drugs. The simi-
larity of the adverse effects of these medications with our patient’s 
clinical presentation of ehrlichiosis proved a diagnostic dilemma. The 
acute drop in an already low platelet count was an early suggestion of 
ehrlichiosis. In general, any patient presenting in the summer months 
with headache, fever, cytopenias, and/or elevated AST/ALT should be 
considered for empiric doxycycline therapy and diagnostic testing. In 
our review, we concluded that individuals with a compromised immune 
system develop more severe disease with Ehrlichiosis spp. It is unknown 
whether this is a product of individual susceptibility or delays in diagno-
sis. It is important to consider tick borne illnesses, including ehrlichiosis, 
in an immunocompromised patient presenting with fevers and cytope-
nias, especially if the patient has a recent history of a tick bite and lives 
in endemic area.
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